Radioisotope
supply chain
excellence
INTRODUCTION TO RLTs
(RADIOLIGAND THERAPIES)
RLTs, a subsegment of precision medicine, are cutting-edge cancer therapies that deliver radiation directly to tumor cells with minimal harm to healthy tissue.
Due to positive patient outcomes, the RLT market has been on a rapid growth trajectory, driving an unprecedented demand for radioisotopes (the payload for RLT therapeutics).
However, enabling patient access is completely dependent on a well-coordinated supply chain that can sustain commercial-scale demand.
So far, supply has not been able to keep up with demand, and the gap is only expected to widen, risking production constraints.
THE ROCKET ISOTOPES
OPPORTUNITY
- Rocket Isotopes is a subsidiary of the Swiss Rockets Group, which is currently developing supply chain solutions, ensuring full control over the production of isotopes, starting with Tb-161.
- Tb-161 is the key radioactive isotope used in Swiss Rockets’ Torpedo therapy targeting prostate cancer and other cancers.
- As the exclusive supply chain partner of Torpedo (with the potential to also extend services to third parties in the future), Rocket Isotopes is well-positioned to unlock the full potential of RLTs and fuel growth for Torpedo’s flagship therapy.
Guaranteed Supply Chain Control
Rocket Isotopes has secured access to raw materials & irradiation facilities and has purification and QC processes in place, while also developing raw material recycling to further strengthen reliability.
Material Upside Potential
As one of the few companies with the capabilities and know-how to produce Tb-161 at scale, Rocket Isotopes will also be able to sell to third-parties, benefiting from a lucrative market opportunity with strong upside potential.
PIONEERING Tb-161 DEVELOPMENT
The scientific team of Rocket Isotopes has been at the forefront of Tb-161 development, creating an unparalleled edge in terms of manufacturing process set-up.
In-house
purification
Established an in-house semi-automated procedure to get Tb-161, with the potential of scaling up for commercial supply.
Excellent
Quality
High purity of Tb-161 makes it suitable for radiolabeling at high specific activities.
Secured synergistic Supply Exclusivity
Rocket Isotopes will be the preferred supplier of Torpedo Pharmaceuticals, part of the Swiss Rockets Group, directly benefiting from the strong demand for Torpedo’s cutting-edge therapies.
HOW IT WORKS
RLTs are cancer treatments that couple a therapeutic radioactive isotope with a cancer-specific cell-targeting molecule – the ligand. When a ligand binds to the cancer cell, its radioactivity is released within the cancer cell to selectively destroy it, offering the potential for improved patient outcomes.
COMMERCIAL OPPORTUNITY
RLTs have been one of the most important milestones achieved in oncology R&D in recent years, being approved for the treatment of prostate cancer, thyroid cancer, and neuroendocrine tumors (NETs).
The RLT market is expected to continue experiencing a rapid growth trajectory due to the strong clinical potential and vast addressable unmet medical need.
$3B
Projected addressable market for therapeutic radioisotopes globally by 2030
RLTs supply is constrained by systemic factors
RLTs supply is constrained by systemic factors
RADIOACTIVITY CONSIDERATIONS
Strict radioactive handling, including regulatory and licensing requirements, complicates operations.
LACK OF
KNOW-HOW
The production and supply of radioisotopes requires deep subject matter expertise and specialized talent.
RAPID MARKET
GROWTH
RLTs are growing rapidly, but their expansion relies on a stable supply of radioisotopes.
HALF-LIFE CHALLENGES
Radioisotopes have short half-lives, challenging supply chain management.
Strong market demand for RLTs is driving continued innovation. However, the supply chain is limited to just a few suppliers and constrained mainly by the needs of Big Pharma.
Therefore, producers require large financial and long-term commitments from new customers, which emerging biotech players are unable to sustain – creating a clear supply-demand imbalance.
